eMedicine Specialties > Dermatology > Parasitic Infections

Onchocerciasis (River Blindness)

Author: Jason F Okulicz, MD, Assistant Professor of Medicine, Uniformed Services University of the Health Sciences; Staff, Infectious Disease Service, Brooke Army Medical Center
Coauthor(s): Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center; Robert A Schwartz, MD, MPH, Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School
Contributor Information and Disclosures

Updated: Feb 13, 2009

Introduction

Background

Onchocerciasis is a common, chronic, multisystemic disease caused by the nematode Onchocerca volvulus. The disease characteristically includes dermatologic, lymphatic, ophthalmologic, and systemic manifestations. Human transmission of the disease is caused by a bite from the intermediate host, the black fly (genus Simulium). Black flies breed along waterways, which can vary from small streams to broad rivers. Affected individuals usually live or work within a few kilometers of these sites. Onchocerciasis has long been associated with a high incidence of detrimental effects on socioeconomic development and public health in endemic areas.

Related eMedicine articles include the following:

Pathophysiology

In 1875, John O'Neill first observed O volvulus microfilariae in a case of "craw-craw," as onchocerciasis is known in West Africa. Almost 50 years later, Blacklock discovered the vector to be Simulium in Sierra Leone. The main vector in most of Africa is Simulium damnosum; in Ethiopia, Uganda, Tanzania, and the Democratic Republic of the Congo, Simulium neavei is common. In the Americas, the principal vectors are Simulium metallicum, Simulium ochraceum, and Simulium exiguum. Some vectors bite humans rather exclusively, whereas others are zoophilic to varying degrees. Animal reservoirs of O volvulus have not been found.

When a black fly takes a blood meal from an infected human, they also ingest onchocercal microfilariae in the skin. Surviving microfilariae in the black fly burst through the peritrophic membrane formed by the blood meal, invade the midgut, and advance to the thoracic muscles. The differentiation of these microfilariae into L1 larva begins in muscle within 28 hours after the blood meal. The first molt produces L2 larva within 96 hours, followed by the second molt, which produces L3 larva by day 7. The infective L3 larva migrates to the insect's head and mouth for future deposition into human skin during the next blood meal.

After L3 larvae are transmitted to human skin, those that survive molt within 1 week to form L4 larva. Their development into male and female forms is completed by 1-3 months. The adult worms reside in the deep dermis and fascial planes. Thick, fibrous, subcutaneous nodules called onchocercomas are formed as the result of the development of scar tissue around the adult worms. These onchocercomas average 3 cm in diameter, and they typically contain 2-3 female adults and 1-2 male adults. The nodules typically are surrounded by eosinophils and lymphocytes that are ready to attack the newly produced microfilariae.

Adult worms isolated in nodules are not directly harmful to the patient. Their progeny, which are released from the nodules, are responsible for most of the damage related to onchocerciasis. Nonetheless, to control the disease, the identification and removal of these onchocercomas is critical. Ivermectin is the most effective agent against microfilariae (see Medical Care). Currently, available agents that are effective against adult worms are toxic. For this reason, surgical removal of the adult worms is important.

Within 10-12 months after the initial infection, adult female worms start producing microfilariae, which have an average lifespan of 6 months to 2 years. The reproductive life of the adult averages 9-11 years. During this time, female worms may release 1300-1900 microfilariae per day. The maximal production of offspring occurs during the first 5 years of the worm's reproductive life, after which this activity declines in a linear fashion.

The microfilariae released from the nodules easily traverse the skin and connective tissue. The subepidermal lymphatics and the anterior chamber of the eye are the most common migration sites. The microfilariae can also be found in the blood, cerebrospinal fluid, urine, and internal organs. More than 100 million microfilariae may be present in severely affected individuals.

A symbiotic relationship has been demonstrated between Wolbachia bacteria and filarial nematodes, including O volvulus.1 Wolbachia species are essential for nematode fertility. Embryogenesis in the female worm is disrupted when Wolbachia numbers are depleted. In addition, murine experiments suggest that corneal inflammation secondary to onchocerciasis may be caused by endotoxins produced by Wolbachia. Results from several small trials suggest that clearance of Wolbachia with antibiotic therapy affects transmission and can reduce and prevent onchocerciasis-related blindness.

Frequency

United States

Onchocerciasis is rare in the United States. All reported cases result from the immigration of individuals from endemic areas.

International

Onchocerciasis is a major public health problem in many parts of the world. The disease is endemic in 37 countries in Africa, Latin America, and Yemen. In 1995, an estimated 123 million people were at risk of contracting the disease according to the World Health Organization Expert Committee on Onchocerciasis. Another 17-18 million people were estimated to be infected.

Approximately 95% of all infected people live in Africa. The disease is most severe along the major rivers in 30 countries across the northern and central areas of the continent. Nigeria, Ethiopia, Cameroon, Uganda, and the Democratic Republic of the Congo have the largest number of infected people.

In Latin America, onchocerciasis can be found in Brazil, Venezuela, Colombia, Ecuador, and Guatemala, as well as in the southern mountainous states of Chiapas and Oaxaca in Mexico.2

Mortality/Morbidity

  • In 1995, an estimated 270,000 people were blinded and another 500,000 had severe visual impairment as a result of the disease.
  • A multicountry study showed that more than 30% of the population in endemic areas have onchocercal dermatitis.
  • In a survey of skin disease in 7 endemic sites in 5 African countries, 40-50% of adults reported troublesome itching. Blindness is not associated with excess mortality. However, increasing microfilarial load is associated with mortality in both males and females.

Race

To the author's knowledge, no current well-described studies have been performed to determine the frequency of onchocerciasis in specific races.

Sex

  • The disease generally affects more men than women, although sex-related differences may not be apparent until the patient reaches a certain age.
  • Sex-related differences are more pronounced in high-transmission areas, particularly the savanna.
  • The overall trend is partially attributed to increased exposures in men, which are related to the occupational risk in farmers, fishermen, and other workers.

Age

The prevalence of onchocerciasis is lowest in individuals aged 0-10 years. Afterward, the prevalence sharply increases, with a peak in individuals aged 20-30 years.

Clinical

History

The most important task is determining if patients in endemic areas have been exposed to O volvulus via the black fly vector.

  • Obtain a detailed travel history if onchocerciasis is suspected. Travelers to endemic areas may have a particularly severe form of dermatitis.
  • Other manifestations of onchocerciasis include weight loss, musculoskeletal pain, inguinal hernias, and systemic embolization of microfilariae.
  • Many patients in endemic regions have associated the disease with secondary amenorrhea, lactation difficulties, spontaneous abortion, infertility, and sterility. However, these associations have never been proven.
  • Patients are asymptomatic in about 10% of cases.

Physical

Localized inflammatory responses to dead or dying microfilariae are almost entirely responsible for the clinical manifestations of the disease. In a severely infected person, 100,000 or more microfilariae die each day. The earliest symptoms are fever, arthralgia, and transient urticaria involving the trunk and face. Onchocercomas, the most characteristic skin lesions, are often present.

  • The following is a summary of the clinical classification system for onchocercal dermatitis, which Murdoch et al developed to standardize and facilitate the collection of data worldwide3 :
    • Acute papular onchodermatitis (APOD) is characterized by a solid, scattered, pruritic papular rash. The diameter of the papules is at least 1 mm. Vesicles or pustules at the apex may or may not be present. The obliteration of the skin creases due to edema also may or may not be present.
    • Chronic papular onchodermatitis (CPOD) involves a scattered, pruritic, hyperpigmented, and flat-topped papulomacular rash. The diameter of the papules is at least 3 mm, with or without excoriations.
    • Lichenified onchodermatitis (LOD) is characterized by raised, discrete, pruritic, and hyperpigmented papulonodular plaques associated with lymphadenopathy. The lesions may be confluent, with or without the presence of excoriations. APOD or CPOD may also be present.
    • Atrophy (ATR) involves wrinkled and dry skin. Firmly pressing the edge of a finger along the skin reveals additional fine wrinkles. In patients younger than 50 years, ATR is scored as a significant abnormality.
    • Depigmentation is characterized by areas of incomplete pigment loss, with associated islands or spots of normal pigment surrounding hair follicles. Leopard skin is similar, except that it is characterized by a complete loss of pigment, with islands or spots of normally pigmented skin around the follicles.
    • Palpable onchocercal nodule is a term used to describe onchocercomas that are palpable at bony prominences.
    • Lymphadenopathy is characterized by lymph nodes 1 cm or larger in diameter. They may or may not be tender.
    • Hanging groin (HG) involves the folds of inelastic, atrophic skin in the inguinal areas. The condition may be unilateral or bilateral, and it may involve enlarged lymph nodes.
    • Lymphedema (LYM) is characterized by edema of a limb or external genitalia.
  • Onchocercomas are fibrous, subcutaneous nodules containing adult worms. These nodules are generally located over bony prominences, and they are easily palpable. Deep nodules, commonly located around the pelvis, can be more difficult to detect. The number of palpable nodules is not correlated with the microfilarial load or the severity of disease. Identifying every nodule is important for proper management.
    • In Africa, the nodules are often observed along the iliac crests, ribs, greater trochanters, and ischial tuberosities. Juxta-articular areas, such as the knees, elbows, patella, and scalp, may also have nodules.
    • In the American forms, nodules are fewer and have a greater tendency to be located on the scalp. In patients with scalp nodules, the risk of ocular complications is generally higher than that of patients without scalp nodules.
    • Onchocercomas are less common in the Yemen form of the disease than in other forms.
  • Onchocercal dermatitis is the most common symptom of the disease.
    • Its initial manifestations, which can occur anywhere on the body, include itching, scratching, and alterations in skin pigmentation.
    • Pruritus may be intermittent and mild, continuous and severe, or absent.
    • A maculopapular rash may appear anywhere on the body at any time.
    • The papules may be small and densely packed or large and separated.
    • The maculopapular rash is often associated with severe pruritus. Excess scratching may lead to bleeding, ulceration, and secondary infection (a condition West Africans call craw-craw).
  • Sowda, a severe form of dermatitis first described in Yemen, is associated with an active delayed hypersensitivity response.
    • Many patients are travelers or temporary workers in nonendemic areas. These patients have dark, thickened, intensely pruritic skin with papules. The regional lymph nodes are soft, nontender, and enlarged.
    • Sowda is usually localized to a single lower extremity.
    • A less common, more generalized form can involve both lower extremities or other parts of the body. Patients have either focal swelling or a more diffuse LYM. Skin-snips do not usually contain microfilariae.
    • Sowda may also be found in patients in West Africa, Ethiopia, Sudan,4 Cameroon, Venezuela, and Ecuador.
  • Leopard skin is a characteristic finding in older patients.
    • Leopard skin involves depigmentation of the pretibial areas of the lower extremities. This pattern is initially seen as discrete depigmented macules, with sparing of the hair follicles.
    • Later, the macules may become confluent, involving a large area of the anterior portion below the knee. This pattern can sometimes be seen in the groin or lower abdomen as well.
  • HG or adenolymphocele is a severe degenerative condition in older individuals.
    • The inguinal and femoral lymph nodes become progressively enlarged and fibrotic, leading to lymphatic obstruction.
    • Concomitantly, progressive destruction of elastic fibers leaves the skin thinned and wrinkled.
    • The atrophied skin tends to hang in apronlike folds under the weight of the accumulating lymphedematous tissue.
    • This condition is more common in men than in women.
  • Ocular manifestations of onchocerciasis are late, serious reactions that occur in about 5% of affected persons.
    • Infection of the cornea produces punctate keratitis in the areas around dead microfilariae. This condition eventually clears when the inflammation settles.
    • Severe and prolonged infection over a number of years is likely to produce sclerosing keratitis, iridocyclitis, and uveitis. Permanent visual impairment, secondary glaucoma, or blindness is often the result.
    • Posterior segment changes may coexist with anterior segment lesions. The changes are caused by inflammation around microfilariae that invade the retina via the posterior ciliary vessels.
    • Choroidoretinal lesions are common around the optic disk or on the outer portion of the macula.
    • Active optic neuritis is a major cause of blindness in many areas with endemic disease.

Causes

In 1875, John O'Neill first observed O volvulus microfilariae in a case of craw-craw, as onchocerciasis is known in West Africa.

  • Almost 50 years later, Blacklock discovered that the vector in Sierra Leone was a Simulium organism. The main vector in most of Africa is S damnosum; in Ethiopia, Uganda, Tanzania, and the Democratic Republic of the Congo, S neavei is common.
  • The principal vectors in the Americas are S metallicum, S ochraceum, and S exiguum.
  • Some vectors bite humans rather exclusively, whereas others are zoophilic to varying degrees. Animal reservoirs of O volvulus have not been found.

More on Onchocerciasis (River Blindness)

Overview: Onchocerciasis (River Blindness)
Differential Diagnoses & Workup: Onchocerciasis (River Blindness)
Treatment & Medication: Onchocerciasis (River Blindness)
Follow-up: Onchocerciasis (River Blindness)
Multimedia: Onchocerciasis (River Blindness)
References

References

  1. Saint Andre A, Blackwell NM, Hall LR, et al. The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river blindness. Science. Mar 8 2002;295(5561):1892-5. [Medline].

  2. Martin-Tellaeche A, Ramirez-Hernandez J, Santos-Preciado JI, Mendez-Galvan J. Onchocerciasis: changes in transmission in Mexico. Ann Trop Med Parasitol. Apr 1998;92 Suppl 1:S117-9. [Medline].

  3. Murdoch ME, Hay RJ, Mackenzie CD, Williams JF, Ghalib HW, Cousens S, et al. A clinical classification and grading system of the cutaneous changes in onchocerciasis. Br J Dermatol. Sep 1993;129(3):260-9. [Medline].

  4. Stingl P. Onchocerciasis: clinical presentation and host parasite interactions in patients of southern Sudan. Int J Dermatol. Jan 1997;36(1):23-8. [Medline].

  5. Stingl P, Ross M, Gibson DW, Ribas J, Connor DH. A diagnostic "patch test" for onchocerciasis using topical diethylcarbamazine. Trans R Soc Trop Med Hyg. 1984;78(2):254-8. [Medline].

  6. Toe L, Adjami AG, Boatin BA, Back C, Alley ES, Dembele N, et al. Topical application of diethylcarbamazine to detect onchocerciasis recrudescence in west Africa. Trans R Soc Trop Med Hyg. Sep-Oct 2000;94(5):519-25. [Medline].

  7. Toe L, Boatin BA, Adjami A, Back C, Merriweather A, Unnasch TR. Detection of Onchocerca volvulus infection by O-150 polymerase chain reaction analysis of skin scratches. J Infect Dis. Jul 1998;178(1):282-5. [Medline].

  8. Rodriguez-Perez MA, Dominguez-Vazquez A, Mendez-Galvan J, et al. Antibody detection tests for Onchocerca volvulus: comparison of the sensitivity of a cocktail of recombinant antigens used in the indirect enzyme-linked immunosorbent assay with a rapid-format antibody card test. Trans R Soc Trop Med Hyg. Sep-Oct 2003;97(5):539-41. [Medline].

  9. Weil GJ, Steel C, Liftis F, et al. A rapid-format antibody card test for diagnosis of onchocerciasis. J Infect Dis. Dec 2000;182(6):1796-9. [Medline].

  10. Ayong LS, Tume CB, Wembe FE, et al. Development and evaluation of an antigen detection dipstick assay for the diagnosis of human onchocerciasis. Trop Med Int Health. Mar 2005;10(3):228-33. [Medline].

  11. Baraka OZ, Mahmoud BM, Ali MM, et al. Ivermectin treatment in severe asymmetric reactive onchodermatitis (sowda) in Sudan. Trans R Soc Trop Med Hyg. May-Jun 1995;89(3):312-5. [Medline].

  12. Burnham G. Ivermectin treatment of onchocercal skin lesions: observations from a placebo-controlled, double-blind trial in Malawi. Am J Trop Med Hyg. Mar 1995;52(3):270-6. [Medline].

  13. Ogbuagu KF, Eneanya CI. A multi-centre study of the effect of Mectizan treatment on onchocercal skin disease: clinical findings. Ann Trop Med Parasitol. Apr 1998;92 Suppl 1:S139-45. [Medline].

  14. Pacque M, Elmets C, Dukuly ZD, et al. Improvement in severe onchocercal skin disease after a single dose of ivermectin. Am J Med. May 1991;90(5):590-4. [Medline].

  15. Debrah AY, Mand S, Marfo-Debrekyei Y, Larbi J, Adjei O, Hoerauf A. Assessment of microfilarial loads in the skin of onchocerciasis patients after treatment with different regimens of doxycycline plus ivermectin. Filaria J. 2006;5:1. [Medline].

  16. Hoerauf A, Specht S, Marfo-Debrekyei Y, et al. Efficacy of 5-week doxycycline treatment on adult Onchocerca volvulus. Parasitol Res. Jan 2009;104(2):437-47. [Medline].

  17. Hoerauf A, Marfo-Debrekyei Y, Buttner M, et al. Effects of 6-week azithromycin treatment on the Wolbachia endobacteria of Onchocerca volvulus. Parasitol Res. Jul 2008;103(2):279-86. [Medline].

  18. Specht S, Mand S, Marfo-Debrekyei Y, et al. Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus. Parasitol Res. Nov 2008;103(6):1303-9. [Medline].

  19. Awadzi K, Opoku NO, Attah SK, et al. The safety and efficacy of amocarzine in African onchocerciasis and the influence of ivermectin on the clinical and parasitological response to treatment. Ann Trop Med Parasitol. Apr 1997;91(3):281-96. [Medline].

  20. Hoerauf A, Volkmann L, Hamelmann C, et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet. Apr 8 2000;355(9211):1242-3. [Medline].

  21. Hoerauf A, Mand S, Adjei O, Fleischer B, Buttner DW. Depletion of wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet. May 5 2001;357(9266):1415-6. [Medline].

  22. Borsboom GJ, Boatin BA, Nagelkerke NJ, et al. Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa. Filaria J. Mar 24 2003;2(1):8. [Medline].

  23. Bandi C, Trees AJ, Brattig NW. Wolbachia in filarial nematodes: evolutionary aspects and implications for the pathogenesis and treatment of filarial diseases. Vet Parasitol. Jul 12 2001;98(1-3):215-38. [Medline].

  24. Boatin BA, Toe L, Alley ES, Dembele N, Weiss N, Dadzie KY. Diagnostics in onchocerciasis: future challenges. Ann Trop Med Parasitol. Apr 1998;92 Suppl 1:S41-5. [Medline].

  25. Burnham G. Onchocerciasis. Lancet. May 2 1998;351(9112):1341-6. [Medline].

  26. Connor DH, Williams PH, Helwig EB, Winslow DJ. Dermal changes in onchocerciasis. Arch Pathol. Feb 1969;87(2):193-200. [Medline].

  27. Duke BO. Onchocerciasis. Br Med Bull. Jan 1972;28(1):66-71. [Medline].

  28. Edgeworth JD, Abiose A, Jones BR. An immunohistochemical analysis of onchocercal nodules: evidence for an interaction between macrophage MRP8/MRP14 and adult Onchocerca volvulus. Clin Exp Immunol. Apr 1993;92(1):84-92. [Medline].

  29. Enk CD. Onchocerciasis--river blindness. Clin Dermatol. May-Jun 2006;24(3):176-80.

  30. Hagan M. Onchocercal dermatitis: clinical impact. Ann Trop Med Parasitol. Apr 1998;92 Suppl 1:S85-96. [Medline].

  31. Kale OO. Onchocerciasis: the burden of disease. Ann Trop Med Parasitol. Apr 1998;92 Suppl 1:S101-15. [Medline].

  32. Lazarov A, Amihai B, Sion-Vardy N. Pruritus and chronic papular dermatitis in an Ethiopian man. Onchocerciasis (chronic papular onchodermatitis). Arch Dermatol. Mar 1997;133(3):382-3, 385-6. [Medline].

  33. Little MP, Breitling LP, Basanez MG, Alley ES, Boatin BA. Association between microfilarial load and excess mortality in onchocerciasis: an epidemiological study. Lancet. May 8 2004;363(9420):1514-21. [Medline].

  34. Martinez RM, Saracho AO. Intramuscular onchocercoma. Case report. J Craniomaxillofac Surg. Aug-Sep 1992;20(6):261-3. [Medline].

  35. Maso MJ, Kapila R, Schwartz RA, Wiltz H, Kaminski ZC, Lambert WC. Cutaneous onchocerciasis. Int J Dermatol. Nov 1987;26(9):593-6. [Medline].

  36. Meyers WM, Neafie RC, Connor DH. Onchocerciasis: invasion of deep organs by Onchocerca volvulus. Am J Trop Med Hyg. Jul 1977;26(4):650-7. [Medline].

  37. Richards F, Hopkins D, Cupp E. Programmatic goals and approaches to onchocerciasis. Lancet. May 13 2000;355(9216):1663-4. [Medline].

  38. Richards FO, Miri E, Meredith S, et al. Onchocerciasis. Bull World Health Organ. 1998;76 Suppl 2:147-9. [Medline].

  39. Rozenman D, Kremer M, Zuckerman F. Onchocerciasis in Israel. Arch Dermatol. Apr 1984;120(4):505-7. [Medline].

  40. Somorin AO. Onchocerciasis. Int J Dermatol. Apr 1983;22(3):182-8. [Medline].

  41. Vernick W, Turner SE, Burov E, Telang GH. Onchocerciasis presenting with lower extremity, hypopigmented macules. Cutis. May 2000;65(5):293-7. [Medline].

Further Reading

Keywords

onchocerciasis, river blindness, African river blindness, blinding filariasis, Robles disease, craw-craw, Onchocerca volvulus, O volvulus, Simulium species, Simulium damnosum, Simulium neavei, Simulium metallicum, Simulium ochraceum, Simulium exiguum, black fly, microfilariae, onchocercal dermatitis, hanging groin, leopard skin, sowda, onchocercal dermatitis, acute papular onchodermatitis, APOD, chronic papular onchodermatitis, CPOD, lichenified onchodermatitis, LOD,

Contributor Information and Disclosures

Author

Jason F Okulicz, MD, Assistant Professor of Medicine, Uniformed Services University of the Health Sciences; Staff, Infectious Disease Service, Brooke Army Medical Center
Jason F Okulicz, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Coauthor(s)

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

Robert A Schwartz, MD, MPH, Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School
Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi
Disclosure: Nothing to disclose.

Medical Editor

Donald Belsito, MD, Clinical Professor, Department of Internal Medicine, Division of Dermatology, University of Missouri at Kansas City; Private Practice, American Dermatology Associates, LLC
Donald Belsito, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Contact Dermatitis Society, Dermatology Foundation, Kansas Medical Society, Noah Worcester Dermatological Society, Phi Beta Kappa, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Pharmacy Editor

David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic
David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Managing Editor

Jeffrey Meffert, MD, Assistant Clinical Professor of Dermatology, University of Texas Health Science Center-San Antonio
Jeffrey Meffert, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Association of Military Dermatologists, and Texas Dermatological Society
Disclosure: Nothing to disclose.

CME Editor

Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University
Catherine Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System
William D James, MD is a member of the following medical societies: American Academy of Dermatology and Society for Investigative Dermatology
Disclosure: elsevier Royalty Other; american college of physicians Honoraria Other

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.